Hydralazine and Valproate Added to Chemotherapy for Breast Cancer
Status:
Terminated
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
Aberrant DNA methylation and histone deacetylation participate in cancer development and
progression, as epigenetic alterations are common to breast cancer, in this phase II study,
the demethylating hydralazine plus the HDAC inhibitor magnesium valproate will be added to
neoadjuvant doxorubicin and cyclophosphamide in locally advanced breast cancer to assess
their safety and biological efficacy.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Cancerología
Collaborators:
National Council of Science and Technology, Mexico Psicofarma S.A. de C.V.